Comparing the Effect of TAP-catheter and Epidural Catheter on Postoperative Pain After Open Gynecologic Surgery
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study compares the effect on postoperative pain of bolus administration of ropivacaine in Transversus abdominis plane catheter and continuous bupivacain-infusion in epidural catheters following open gynecologic surgery.The study is double blind. The hypothesis is that the effect of the two modes of pain treatment are equal.
| Condition | Intervention |
|---|---|
|
Pain, Postoperative |
Drug: Ropivacaine bolus in transversus abdominis plane catheter Drug: Bupivacain-infusion in epidural catheter |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Randomized Double Blind Trial Comparing the Effect of Transversus Abdominal Plane-catheter and Epidural Catheter on Postoperative Pain After Open Gynecologic Surgery |
- Pain-score on numerical rating scale [ Time Frame: 4 hours after first bolus in tranversus abdominis catheters ] [ Designated as safety issue: No ]
- Administration of opioids [ Time Frame: The first 24 hours after surgery. ] [ Designated as safety issue: No ]
- Pain-score on numerical rating scale [ Time Frame: 8 hours after first bolus in tranversus abdominis catheters ] [ Designated as safety issue: No ]
- Pain-score on numerical rating scale [ Time Frame: 24 hours after first bolus in tranversus abdominis catheters ] [ Designated as safety issue: No ]
- Thermoanalgesia at dermatome-level th10-th12 [ Time Frame: 4 hours after first bolus in TAP-catherter ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 80 |
| Study Start Date: | January 2013 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Bupivacain-infusion in epidural catheter
Bupivacain-infusion in epidural catheter and intermittent isotonic potassium chloride bolus in transversus abdominis plane catheter.
|
Drug: Bupivacain-infusion in epidural catheter
Isotonic potassium chloride, 10-25 ml in each transversus abdominis catheter, depending on patient weight. Bolus is given every 6 hours, the first bolus is given just after induction of general anesthesia and the last bolus after 24 hours. In the epidural catheter a bolus of 8 ml bupivacaine 2,5 mg/ml is given and an infusion of isotonic potassium chloride, 4-7 ml/t depending on patient height is started and runs for the first 24 hours |
|
Active Comparator: Ropivacaine bolus in transversus abdominis plane catheter
Intermittent ropivacaine bolus in bilateral transversus abdominis plane catheter and isotonic potassium chloride infusion in epidural catheter.
|
Drug: Ropivacaine bolus in transversus abdominis plane catheter
Ropivacaine 7,5 mg/ml, 10-25 ml in each catheter, depending on patient weight, the total dose of ropivacaine is kept less than 3 mg/kg for every bolus. Bolus is given every 6 hours, the first bolus is given just after induction of general anesthesia and the last bolus after 24 hours. In the epidural catheter a bolus of 8 ml isotonic potassium chloride is given and an infusion of isotonic potassium chloride, 4-7 ml/t depending on patient height is started and runs for the first 24 hours. |
Detailed Description:
Patients for open gynecologic surgery will all receive both an epidural catheter and bilateral transversus abdominis plane (:TAP) catheters. After randomization in to two groups the patients receive either 1) intermittent boluses of ropivacaine in the TAP-catheters and isotonic potassium chloride-infusion i the epidural catheters or 2) intermittent isotonic potassium chloride-boluses i the TAP-catheters and bupivacain-infusion in the epidural catheters.
The investigators record pain-score and consumption of opioids in the first 24 hours postoperatively as well as thermoanalgesia at dermatome-levels th10-th12.
The investigators assume that the effect on postoperative pain after open gynecologic surgery is equal in the two groups.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- patients scheduled for open gynecologic surgery
- acceptance to participate
Exclusion Criteria:
- allergies to local analgetics
- daily use of strong opioids
Contacts and Locations| Contact: Nils F Bjerregaard, M.D. | 0045 22 86 06 49 | niheb@rn.dk |
| Denmark | |
| Aalborg Hospital | Not yet recruiting |
| Aalborg, Region Nord, Denmark, 9000 | |
| Contact: Nils F Bjerregaard, MD 0045 22 86 06 49 niheb@rn.dk | |
| Principal Investigator: Nils F Bjerregaard, M.D. | |
| Principal Investigator: | Nils F Bjerregaard, M.D. | Aalborg Universityhospital |
| Study Director: | Bodil S Rasmussen, M.D. + PhD | Aalborg Sygehus |
| Study Chair: | Lone Nikolajsen, M.D, PhD | Aarhus University Hospital |
| Study Chair: | Thomas F Bendtsen, MD, PhD | Aarhus University Hospital |
More Information
No publications provided
| Responsible Party: | Nils Bjerregaard, Consultant Anesthetist, Aalborg Hospital |
| ClinicalTrials.gov Identifier: | NCT01760174 History of Changes |
| Other Study ID Numbers: | N-20120041 |
| Study First Received: | July 26, 2012 |
| Last Updated: | January 2, 2013 |
| Health Authority: | Denmark: The Regional Committee on Biomedical Research Ethics |
Keywords provided by Aalborg Universityhospital:
|
Transversus abdominis plane catheter |
Additional relevant MeSH terms:
|
Pain, Postoperative Postoperative Complications Pathologic Processes Pain Signs and Symptoms Bupivacaine Ropivacaine Anesthetics, Local |
Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 23, 2013